Advertisement
Retraction
Open Access | 10.1172/JCI198608
Find articles by Yang, J. in: PubMed | Google Scholar
Find articles by Jiang, Z. in: PubMed | Google Scholar
Find articles by Fitzgerald, D. in: PubMed | Google Scholar
Find articles by Ma, C. in: PubMed | Google Scholar
Find articles by Yu, S. in: PubMed | Google Scholar
Find articles by Li, H. in: PubMed | Google Scholar
Find articles by Zhao, Z. in: PubMed | Google Scholar
Find articles by Li, Y. in: PubMed | Google Scholar
Find articles by Ciric, B. in: PubMed | Google Scholar
Find articles by Curtis, M. in: PubMed | Google Scholar
Find articles by Rostami, A. in: PubMed | Google Scholar
Find articles by Zhang, G. in: PubMed | Google Scholar
Published September 16, 2025 - More info
Adult neural stem cells (aNSCs) derived from the subventricular zone of the brain show therapeutic effects in EAE, an animal model of the chronic inflammatory neurodegenerative disease MS; however, the beneficial effects are modest. One critical weakness of aNSC therapy may be an insufficient antiinflammatory effect. Here, we demonstrate that i.v. or i.c.v. injection of aNSCs engineered to secrete IL-10 (IL-10–aNSCs), a potent immunoregulatory cytokine, induced more profound functional and pathological recovery from ongoing EAE than that with control aNSCs. IL-10–aNSCs exhibited enhanced antiinflammatory effects in the periphery and inflammatory foci in the CNS compared with control aNSCs, more effectively reducing myelin damage, a hallmark of MS. When compared with mice treated with control aNSCs, those treated with IL-10–aNSCs demonstrated differentiation of transplanted cells into greater numbers of oligodendrocytes and neurons but fewer astrocytes, thus enhancing exogenous remyelination and neuron/axonal growth. Finally, IL-10–aNSCs converted a hostile environment to one supportive of neurons/oligodendrocytes, thereby promoting endogenous remyelination. Thus, aNSCs engineered to express IL-10 show enhanced ability to induce immune suppression, remyelination, and neuronal repair and may represent a novel approach that can substantially improve the efficacy of neural stem cell–based therapy in EAE/MS.
Jingxian Yang, Zhilong Jiang, Denise C. Fitzgerald, Cungen Ma, Shuo Yu, Hongmei Li, Zhao Zhao, Yonghai Li, Bogoljub Ciric, Mark Curtis, Abdolmohamad Rostami, Guang-Xian Zhang
Original citation: J Clin Invest. 2009;119(12):3678–3691. https://doi.org/10.1172/JCI37914
Citation for this retraction: J Clin Invest. 2025;135(18):e198608. https://doi.org/10.1172/JCI198608
Errors made using image editing software were identified in Figure 6B and Supplemental Figure 4B. The Editors are retracting the article due to misrepresentation of data.
Guang-Xian Zhang dissents from the Journal’s decision to retract. The remaining authors abstained from commenting or could not be reached.